Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYL-02
- Development stage
- Phase 2
- Lead developer
- InvivoGen
- Modality
- Gene Therapies
- Administration
- Intratumoral
01
Overview
CYL-02 is a plasmid-based gene therapy product designed to sensitize pancreatic cancer cells to chemotherapy. It contains a plasmid DNA encoding mouse somatostatin receptor subtype 2 (sst2) and a fusion protein of human deoxycytidine kinase (DCK) and uridine monophosphate kinase (UMK). When administered intratumorally via endoscopic ultrasound, CYL-02 delivers therapeutic DNA to tumors, resulting in long-term anticancerous gene expression. It is typically used in combination with gemcitabine for the treatment of advanced pancreatic cancer.
- Other names
- CYL-02 plasmid DNACYL02 plasmid DNACYL 02 plasmid DNA
02
Targets
CMPK1 (Deoxycytidylate kinase)SSTR2 (Somatostatin receptor type 2)DCK (Deoxycytidine kinase)
Beyond the preview
Go deeper on CYL-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYL-02.